Slingshot Insights | Ptgx Overview

PTGX Overview

Upcoming Projects (PTGX)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (PTGX)

A Third Look: Diving into the recent Phase 2b ANTHEM-UC clinical trial of icotrokinra in patients with ulcerative colitis.
Ticker: PTGX
Executed On: May 14, 2025 at 12:00 PM EDT
A Third View: Discussing Janssen/Protagonist Therapeutics recent Icotrokinra Results Showing 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill
Tickers: JNJ, PTGX
Executed On: May 12, 2025 at 04:15 PM EDT
A Second View: Discussing Janssen/Protagonist Therapeutics recent Icotrokinra Results Showing 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill
Tickers: JNJ, PTGX
Executed On: Apr 29, 2025 at 04:00 PM EDT
A Third Look: Discussing the results from the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment.
Ticker: PTGX
Executed On: Apr 28, 2025 at 10:00 AM EDT
Discussing Janssen/Protagonist Therapeutics recent Icotrokinra Results Showing 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill
Tickers: JNJ, PTGX
Executed On: Apr 28, 2025 at 10:00 AM EDT
A Second Look: Diving into the recent Phase 2b ANTHEM-UC clinical trial of icotrokinra in patients with ulcerative colitis.
Ticker: PTGX
Executed On: Apr 21, 2025 at 08:30 AM EDT
A Second Look: Discussing the results from the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment.
Ticker: PTGX
Executed On: Apr 16, 2025 at 02:15 PM EDT
Discussing the results from the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera were randomized to treatment with either rusfertide or placebo, as an add-on to standard of care treatment.
Ticker: PTGX
Executed On: Apr 15, 2025 at 05:05 AM EDT
Third View: Discussing Johnson & Johnson's Phase 3 results icotrokinra, an investigational targeted oral peptide that selectively blocks the IL-23 receptor for patients with psoriasis.
Tickers: JNJ, PTGX
Executed On: Apr 03, 2025 at 04:15 PM EDT
Second View: Discussing Johnson & Johnson's Phase 3 results icotrokinra, an investigational targeted oral peptide that selectively blocks the IL-23 receptor for patients with psoriasis.
Tickers: JNJ, PTGX
Executed On: Apr 01, 2025 at 08:45 AM EDT
Discussing Johnson & Johnson's Phase 3 results icotrokinra, an investigational targeted oral peptide that selectively blocks the IL-23 receptor for patients with psoriasis.
Tickers: JNJ, PTGX
Executed On: Mar 27, 2025 at 02:00 PM EDT
Diving into the recent Phase 2b ANTHEM-UC clinical trial of icotrokinra in patients with ulcerative colitis.
Ticker: PTGX
Executed On: Mar 20, 2025 at 02:00 PM EDT
A Third Look: Discussing the topline results from the Phase 3 ICONIC-LEAD Study of icotrokinra (JNJ-2113), an oral peptide targeting the IL-23 receptor, in patients 12 years of age and older with moderate to severe plaque psoriasis.
Tickers: JNJ, PTGX
Executed On: Dec 11, 2024 at 10:00 AM EST
A Second Look: Discussing the topline results from the Phase 3 ICONIC-LEAD Study of icotrokinra (JNJ-2113), an oral peptide targeting the IL-23 receptor, in patients 12 years of age and older with moderate to severe plaque psoriasis.
Tickers: JNJ, PTGX
Executed On: Dec 06, 2024 at 12:30 PM EST
Discussing the topline results from the Phase 3 ICONIC-LEAD Study of icotrokinra (JNJ-2113), an oral peptide targeting the IL-23 receptor, in patients 12 years of age and older with moderate to severe plaque psoriasis.
Tickers: JNJ, PTGX
Executed On: Dec 05, 2024 at 04:00 PM EST

Upcoming & Overdue Catalysts (PTGX)

Don’t see a catalyst related to the company you care about? Create your own!

Strategic Initiatives (PTGX)

Don’t see a strategic initiative related to the company you care about? Create your own!